Downregulation of α-enolase (ENO1) Inhibits Growth, Invasion, and Metastasis of Human Cervical Cancer Cells

Objectives: The aerobic glycolysis is a characteristic of cancer. α-enolase (ENO1) is an important glycolytic enzyme and is suggested to play a role in the development of tumor. The purpose of this study was to investigate the effects of ENO1 on growth, invasion, and metastasis of human cervical cancer cells. Methods: We knocked down gene coding ENO1 in Hela and SiHa cells with lentivirus, which was confirmed by western-blot. Following downregulation of ENO1, the drug sensitivity, invasion, metastasis, tumourigenic abilities of ENO1-altered cells were investigated. Results: Our studies demonstrated that downregulation of ENO1 enhanced the sensitivity of Hela and SiHa cells to paclitaxel and cisplatin and decreased their tumorigenicity. In addition, the abilities of invasion, metastasis, and tumourigenesis were decreased in ENO1-silenced Hela and SiHa cells. Conclusions: ENO1 is involved in the tumorigenicity, invasion, metastasis, and drug sensitivity of Hela and SiHa cells.

α-enolase; Drug sensitivity; Cell tumorigenicity; Invasion and metastasis.

[1] Doorbar J.: “Molecular biology of human papillomavirus infection and cervical cancer”. Clin. Sci., 2006, 110, 525-541.

[2] Vjpeyi R.: “WHO classification of tumor: Pathology and genet-ics tumors of the breast and female genital organs”. J. Clin. Pathol, 2003, 58, 671-627.

[3] Cox J.T.: “Human Papillomavirus Testing in Primary Cervical Screening and Abnormal Papanicolaou Management”. Obstetrical & Gynecological Survey, 2006, 61, S15-S25.

[4] Parkin D.M.: “Global cancer statistics in the year 2000”. the Lancet Oncology, 2001, 2, 533-543.

[5] Knaul F.M., Bhadelia A., Gralow J., Arreola-Ornelas H., Langer A., Frenk J.: “Meeting the emerging challenge of breast and cervical cancer in low- and middle-income countries”. International Journal of Gynecology & Obstetrics, 2012, 119, S85-S88.

[6] Warburg O.: “On the Origin of Cancer Cells”. Science, 1956, 123, 309- 314.

[7] Majumder P.K., Febbo G.P., Bikoff R., Berger R., Xue Q., McMa-hon L.M., et al.: “mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways”. Nat. Med., 2004, 10, 594–601.

[8] Shackelford D.B., Vasquez D.S., Corbeil J., Wu S., Leblanc M., Wu C. L., et al.: “mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome”. Proc Natl Acad Sci U S A, 2009. 106, 11137–11142.

[9] Palaskas N., Larson S.M., Schultz N., Komisopoulou E., Wong J., Rohle D., et al.: “18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers”. Cancer Res., 2011, 71, 5164-5174.

[10] Vander Heiden M.G.: “Targeting cancer metabolism: a therapeutic window opens”. Nature Reviews Drug Discovery, 2011, 10, 671-684.

[11] Tennant D.A., Durán R.V., Gottlieb E.: “Targeting metabolic transformation for cancer therapy”. Nature Reviews Cancer, 2010, 10, 267- 277.

[12] Pancholi V.: “Multifunctional alphaenolase: its role in diseases”. Cell Mol Life Sci, 2001, 58, 902–920.

[13] Kim J., Dang C.V.: “Multifaceted roles of glycolytic enzymes”. Trends Biochem. Sci., 2005, 30, 142-150.

[14] Chang Y.S., Wu W., Walsh G., Hong W.K., Mao L.: “Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior”. Clin Cancer Res, 2003, 9, 3641–3644.

[15] Wu W., Tang X., Hu W., Lotan R., Hong W.K., Mao L.: “Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry”. Clin Exp Metastasis, 2002. 19, 319-26.

[16] Tu S.H., Chang C.C., Chen C.S., Tam K.W., Wang Y.J., Lee C.H., et al.: “Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells”. Breast Cancer Res Treat, 2010. 121, 539-553.

[17] Keall P.J., Lammering G., Lin P., Winter D.S., Chung T.D., Mo-han R., et al.: “Tumor control probability predictions for genetic radiotherapy”. International Journal of Radiation Oncol-ogy*Biology*Physics, 2003, 57, 255-263.

[18] Chang G.C., Liu K.J., Hsieh C.L, Hu T.S., Charoenfuprasert S., Liu H. K., et al., “Identification of aipha-enolase as an antoantigen in lung cancer. Its overexpression is associated with clinical outcomes“. Clin Cancer Res, 2006, 12, 5746-5754.

[19] Stierum R., Gaspari M., Dommels Y., Ouatas T., Pluk H., Jespersen S., et al.: “Proteome analysis reveals novel proteins associated with proliferation and differentiation of the colorectal cancer cell line Caco-2”. Biochimica Et Biophysica Acta (BBA) - Proteins and Pro-teomics, 2003, 1650, 73-91.

[20] Lin L., Huang H., Juan H.: “Discovery of biomarkers for gastric cancer: A proteomics approach”. Journal of Proteomics, 2012, 75, 3081-3097.

[21] Baris O., Savagner F., Nasser V., Loriod B., Granjeaud S., Guyetant S., et al.: “Transcriptional Profiling Reveals Coordinated Up-Regulation of Oxidative Metabolism Genes in Thyroid Oncocytic Tumors”. the Journal of Clinical Endocrinology & Metabolism, 2004, 89, 994-1005.

[22] Tsai S., Chien I., Shen W., Kuo Y., Jin Y., Wong T., et al.: “ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction”. Eur. J. Cancer, 2010, 46, 1712-1723.

[23] Tischer E., Gospodarowicz D., Mitchell R., Silva M., Schilling J., Lau K., et al.: “Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family”. Biochem. Biophys. Res. Commun., 1989, 165, 1198-1206.

[24] Potapovich, A.I., Lulli D., Fidanza P., Kostyuk V.A., Luca C.D., Pastore S., et al.: “Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFκB and AhR and EGFR-ERK pathway”. Toxicol Appl Pharmacol, 2011. 255, 138-49.

[25] Hrabec E., Naduk J., Strek M., Hrabec Z.: “Type IV collagenases (MMP-2 and MMP-9) and their substrates–intracellular proteins, hormones, cytokines, chemokines and their receptors”. Postepy Biochem, 2007, 53, 37-45.

[26] Umar A., Viner J.L., Anderson W.F., Hawk E.T.: “Development of COX inhibitors in cancer prevention and therapy”. Am J Clin Oncol, 2003, 26, S48-57.

[27] Lieto E., Ferraraccio F., Orditura M., Castellano P., Mura A.L., Pinto M., et al.: “Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients”. Ann. Surg. Oncol., 2008, 15, 69-79.

[28] Shin V.Y.: “Nicotine promotes gastric tumor growth and neovas-cularization by activating extracellular signal-regulated kinase and cyclooxygenase-2”. Carcinogenesis, 2004, 25, 2487-2495.